Table 4 Pharmacokinetic parameters for S-1 and eribulin
From: A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
Level 1 | Level 2 | Level 3 | ||||
|---|---|---|---|---|---|---|
Parameter | 5-FU | Eribulin | 5-FU | Eribulin | 5-FU | Eribulin |
Cmax (ng ml−1) | 127.3±19.1 | 186.7±83.6 | 141.7±67.4 | 386.1±77.9 | 219.2±110.8 | 593.8±139.7 |
t1/2 (h) | 3.4±2.1 | 33.3±24.0 | 2.6±0.7 | 33.7±22.7 | 2.7±1.0 | 12.9±13.8 |
AUC0–inf (ng ml−1 h) | 902.6±157.1 | 479.4±281.5 | 753.6±387.3 | 621.2±454.5 | 1145±694.4 | 444.9±146.3 |
CL (L h−1 m−2) | 64.9±13.3 | 3.5±3.1 | 86.2±34.2 | 4.3±4.5 | 76.0±29.0 | 3.4±0.9 |
Vz (l m−2) | 294.2±144.7 | 99.1±33.4 | 330.3±189.2 | 111.9±27.7 | 283.8±138.2 | 51.7±33.2 |
MRT (h) | 6.1±2.6 | 24.2±17.9 | 4.6±0.5 | 22.1±15.4 | 4.7±1.5 | 7.5±7.3 |
